68 / 100

Dr YUKSEL ÇETİN | Functional Biomaterials | Best Researcher Award 🏆

Chief Researcher at The Scientific and Technological Research Council (TUBITAK), Marmara Research Center (MAM)🎓

Dr. Yüksel Çetin is the Chief Researcher at the Life Sciences, Medical Biotechnology Unit of TUBITAK’s Marmara Research Centre, Turkey. He earned his PhD in Food Science and Technology from the University of Nebraska-Lincoln, with a minor in Toxicology. His postdoctoral work focused on pulmonary disease pathogenesis through the FP 6 PULMONET project. Yüksel specializes in in vivo and in vitro toxicology, studying novel drugs, biomaterials, and nanoparticles. He leads several funded projects, including NANOBIO4CAN for cancer therapies and the development of 3D cardiac patches. His commitment to innovation and safety in biotechnology highlights his significant contributions to the field.

 

Professional Profile 

Education 🎓

Yüksel Çetin earned his PhD in Food Science and Technology from the University of Nebraska-Lincoln, USA, with a minor in Toxicology from the Toxicology Centre for Environmental Toxicology at the Eppley Institute for Research in Cancer and Allied Diseases. His postdoctoral research focused on the pathogenesis of pulmonary disease through the FP 6 PULMONET Marie Curie Project at the European Commission’s Joint Research Centre.

Work Experience 🏢

Currently serving as Chief Researcher at the Life Sciences, Medical Biotechnology Unit of the Scientific & Technological Research Council of Turkey (TUBITAK) at the Marmara Research Centre, Yüksel has held multiple leadership roles in various research projects, overseeing significant budgets and collaborative efforts aimed at advancing medical biotechnology and toxicology.

Skills 🔬

Yüksel possesses extensive expertise in in vivo and in vitro toxicology, molecular mechanisms of drugs, biomaterials, and medical devices. His proficiency in three-dimensional bioprinting technology and nanoparticle research is complemented by a robust background in evaluating the pathogenicity of xenobiotics.

Awards and Honors 🏆

He has been recognized for his innovative contributions to medical biotechnology and has received multiple grants and funding for his research projects, underlining his reputation as a leader in the field.

Membership 🌍

Yüksel is an active member of various scientific organizations and advisory boards, including involvement in Horizon 2020 projects focused on nanotechnology and safety assessments, emphasizing his commitment to advancing scientific research and innovation.

Teaching Experience 👨‍🏫

With a wealth of knowledge, Yüksel has shared his expertise through teaching roles at various academic institutions, focusing on topics related to food science, toxicology, and medical biotechnology, mentoring the next generation of scientists.

Research Focus 🔍

His research primarily investigates the toxicological effects of novel drugs, biomaterials, and nanoparticles, as well as the development of innovative therapeutic approaches for cancer treatment. Yüksel’s projects encompass antiviral research, tissue regeneration, and vaccine development, demonstrating his dedication to impactful scientific advancements.

 

Publications : 

  • Cytotoxicity of Fusarium mycotoxins to mammalian cell cultures as determined by the MTT bioassay
    Year: 2005
    Journal: Food and Chemical Toxicology
  • In vitro evaluation of the toxicity induced by nickel soluble and particulate forms in human airway epithelial cells
    Year: 2011
    Journal: Toxicology in vitro
  • Evaluation of reduced toxicity of zearalenone by extrusion processing as measured by the MTT cell proliferation assay
    Year: 2005
    Journal: Journal of Agricultural and Food Chemistry
  • Characterisation of cadmium chloride induced molecular and functional alterations in airway epithelial cells
    Year: 2009
    Journal: Cellular Physiology and Biochemistry
  • Evaluation of the molecular mechanisms of a palladium (II) saccharinate complex with terpyridine as an anticancer agent
    Year: 2014
    Journal: Anti-Cancer Drugs
  • A novel system to study the impact of epithelial barriers on cellular metabolism
    Year: 2000
    Journal: Annals of Biomedical Engineering
  • Confirmation of reduced toxicity of deoxynivalenol in extrusion-processed corn grits by the MTT bioassay
    Year: 2006
    Journal: Journal of Agricultural and Food Chemistry
  • The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies
    Year: 2022
    Journal: Molecular Therapy
  • The Development of Novel Approaches to the Identification of Chemical and Protein Respiratory Allergens: Progress made from the Conclusions and Recommendations of ECVAM Workshop 60
    Year: 2008
    Journal: Alternatives to Laboratory Animals
  • Fabrication of a dual-drug-loaded smart niosome-g-chitosan polymeric platform for lung cancer treatment
    Year: 2023
    Journal: Polymers
  • Instant determination of the artemisinin from various Artemisia annua L. extracts by LC‐ESI‐MS/MS and their in‐silico modelling and in vitro antiviral activity
    Year: 2022
    Journal: Phytochemical Analysis
  • A palladium (II)–saccharinate complex of terpyridine exerts higher anticancer potency and less toxicity than cisplatin in a mouse allograft model
    Year: 2017
    Journal: Anti-Cancer Drugs
Dr YUKSEL ÇETİN | Functional Biomaterials | Best Researcher Award

You May Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *